Reza Mehrazin, MD
img_Reza Mehrazin
Are you a patient?
Research Topics
Anti-Tumor Therapy, Cancer, Imaging, Kidney, Patient Care, Patient Centered Outcomes Research, Prostate, Robotic Surgery, Technology & Innovation

·        Dr. Mehrazin has clinical and laboratory research interests in identifying biomarkers, anticancer agents and cutting-edge technologies to improve long-term surgical and functional outcomes in patients with various urologic cancers.


“I understand the emotional burden that diagnosis of cancer can have on the patient and family members.  I always would treat my patients as I would treatment my own family and friends.  I understand quality of life is superbly important and would personalize treatment for each patient through extensive discussions and effective communication.”

MD, Medical University of the Americas-Nevis

Internship, Surgery (General Surgery), University of Tennessee Health Sciences Center

Residency, Urology, University of Tennessee Health Sciences Center

Fellowship, Urologic Oncology, Fox Chase Cancer Center


American Board of Urology


American Urological Association Leadership Program


Resident Teaching Award

Mount Sinai School of Medicine Department of Urology

Castle Connolly Top Doctors

Super Doctors

New York Rising Stars

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Dr. Mehrazin has not yet completed reporting of Industry relationships.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.